If Kesimpta Isn't Approved by Blue Cross Blue Shield in New York: Formulary Alternatives & Exception Paths
Answer Box: Kesimpta Alternatives with BCBS New York
If Blue Cross Blue Shield denies Kesimpta (ofatumumab) in New York, formulary alternatives include Ocrevus, Tysabri, Tecfidera, and interferon-based DMTs. Most BCBS NY plans require step therapy with oral or injectable DMTs before approving high-cost biologics. Your fastest path: request a formulary